Fulcrum Therapeutics (FULC) Scheduled to Post Earnings on Wednesday

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) will be issuing its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Fulcrum Therapeutics Price Performance

FULC stock traded up $0.05 during mid-day trading on Thursday, hitting $3.48. 1,159,132 shares of the stock were exchanged, compared to its average volume of 995,357. The business has a fifty day moving average price of $4.46 and a 200 day moving average price of $6.66. Fulcrum Therapeutics has a 12 month low of $2.87 and a 12 month high of $13.70. The stock has a market capitalization of $217.15 million, a price-to-earnings ratio of -10.06 and a beta of 2.24.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on FULC shares. Cantor Fitzgerald cut Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 12th. Royal Bank of Canada downgraded shares of Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price target for the company from $15.00 to $4.00 in a report on Thursday, September 12th. Leerink Partners reaffirmed a "market perform" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Bank of America downgraded Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and dropped their price target for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Finally, Stifel Nicolaus cut Fulcrum Therapeutics from a "buy" rating to a "hold" rating and decreased their target price for the stock from $22.00 to $3.00 in a report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.